Is there a role for cytokine-induced killer cells in cancer immunotherapy?

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 867-869

  Rutella, Sergio ^a,b   Locatelli, Franco ^a,b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Thymoglobulin ; cancer; cytokine induced killer cells; IFN ; IL 2; immunotherapy

Indexed keywords

CD34 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CYTOKINE INDUCED KILLER CELL; EFFECTOR CELL; GOOD MANUFACTURING PRACTICE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOCYTE TRANSFER; METASTATIC MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

CYTOKINE-INDUCED KILLER CELLS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84867341013     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.89     Document Type: Review

References (20)

1. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010).
2. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
3. Ustun C, Miller JS, Munn DH et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118(19), 5084-5095 (2011).
4. Gabrilovich DI, Bronte V, Chen SH et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67(1), 425; author reply 426 (2007). (Pubitemid 46142802)
5. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6(5), 392-401 (2006).
6. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
7. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153(4), 1687-1696 (1994). (Pubitemid 24251113)
8. Hoyle C, Bangs CD, Chang P et al. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92(9), 3318-3327 (1998). (Pubitemid 28492340)
9. Introna M, Borleri G, Conti E et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a Phase I study. Haematologica 92(7), 952-959 (2007). (Pubitemid 350144242)
10. Leemhuis T, Wells S, Scheffold C et al. A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 11(3), 181-187 (2005). (Pubitemid 40287916)
11. Olioso P, Giancola R, Di Riti M et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol. Oncol. 27(3), 130-139 (2009).
12. Schmidt-Wolf IG, Negrin RS, Kiem HP et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174(1), 139-149 (1991).
13. Mehta BA, Schmidt-Wolf IG, Weissman IL et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 86(9), 3493-3499 (1995).
14. Verneris MR, Karami M, Baker J et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103(8), 3065-3072 (2004). (Pubitemid 38451682)
15. Pievani A, Borleri G, Pende D et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118(12), 3301-3310 (2011).
16. Bonanno G, Iudicone P, Mariotti A et al. Thymoglobulin, interferon-g and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J. Transl Med. 8, 129 (2010).
17. Rutella S, Iudicone P, Bonanno G et al. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14(7), 841-850 (2012).
18. Hontscha C, Borck Y, Zhou H et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 137(2), 305-310 (2011).
19. Laport GG, Sheehan K, Baker J et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 17(11), 1679-1687 (2011).
20. Rettinger E, Meyer V, Kreyenberg H et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front. Oncol. 2(1), 32 (2012).